Clinical Trials Logo

Clinical Trial Summary

1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05811975
Study type Interventional
Source TCRx Therapeutics Co.Ltd
Contact clinical trials ksh
Phone 18994103369
Email ksh-clinicalt@tcrximmune.com
Status Recruiting
Phase Early Phase 1
Start date March 7, 2023
Completion date December 31, 2028

See also
  Status Clinical Trial Phase
Completed NCT00404508 - A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors Phase 2
Completed NCT02450136 - Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors N/A
Completed NCT02596503 - A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT00759928 - PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors Phase 1
Recruiting NCT06150365 - Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors Early Phase 1
Completed NCT01247168 - An Open-Label, Dose-Escalation Study of AZD2461 Phase 1
Completed NCT00665990 - Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia Phase 1
Completed NCT02691793 - Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors Phase 4
Completed NCT02450149 - Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors N/A
Completed NCT02691767 - Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors N/A
Terminated NCT00664586 - A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors Phase 1
Completed NCT03810742 - Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors Phase 1
Terminated NCT03096340 - Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer Phase 1
Completed NCT02450123 - Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors N/A
Completed NCT02383368 - A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma Phase 1
Completed NCT00394446 - Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors Phase 1
Completed NCT03052205 - A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors Phase 1
Completed NCT02482441 - A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Phase 1
Recruiting NCT03739827 - Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Recruiting NCT05150457 - Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors Phase 1